Infectious intracranial aneurysm
| Infectious intracranial aneurysm | |
|---|---|
| Synonyms | Mycotic aneurysm |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Headache, fever, neurological deficits |
| Complications | Subarachnoid hemorrhage, stroke |
| Onset | Variable |
| Duration | Variable |
| Types | N/A |
| Causes | Bacterial infection, often endocarditis |
| Risks | Intravenous drug use, immunosuppression |
| Diagnosis | CT scan, MRI, cerebral angiography |
| Differential diagnosis | Saccular aneurysm, vasculitis |
| Prevention | Treating underlying infections |
| Treatment | Antibiotics, surgical intervention |
| Medication | N/A |
| Prognosis | Variable, depends on rupture and treatment |
| Frequency | Rare |
| Deaths | N/A |
Infectious intracranial aneurysm (IIA), also known as mycotic aneurysm, is a rare form of aneurysm that occurs within the cranium (skull) due to an infection. These aneurysms are typically associated with bacterial or fungal infections that affect the arterial walls, leading to their weakening and subsequent ballooning. The term "mycotic" historically referred to fungal infections, but in the context of IIA, it encompasses any infection of the arterial wall, not limited to fungal etiologies.
Causes
Infectious intracranial aneurysms are most commonly caused by bacterial infections, with the Staphylococcus aureus and Streptococcus species being the predominant pathogens. These infections can reach the cerebral arteries through various routes, including septic emboli from a distant infectious source (e.g., endocarditis), direct extension from adjacent infections (such as sinusitis or mastoiditis), or as a complication of bacterial meningitis. Fungal causes, though less common, include species such as Aspergillus and Candida.
Pathophysiology
The pathogenesis of IIA involves the infection of the arterial wall, leading to its weakening. Infectious agents can invade the arterial wall directly or via circulating emboli. Once the arterial wall is infected, it can lead to the formation of an aneurysm through inflammatory damage and necrosis of the vessel wall. This process weakens the structural integrity of the artery, causing it to dilate and form an aneurysm.
Symptoms
Symptoms of an infectious intracranial aneurysm can vary widely depending on the aneurysm's size, location, and rate of growth. Common symptoms include headache, nausea, vomiting, neurological deficits (such as weakness or numbness in parts of the body), and in severe cases, subarachnoid hemorrhage (SAH) due to rupture of the aneurysm. SAH presents with a sudden, severe headache often described as the "worst headache of one's life," along with neck stiffness, photophobia, and possibly loss of consciousness.
Diagnosis
Diagnosis of IIA involves a combination of clinical assessment, laboratory tests, and imaging studies. Blood cultures may identify the causative organism. Imaging techniques such as computed tomography angiography (CTA) and magnetic resonance angiography (MRA) are crucial for visualizing the aneurysm's size, location, and relation to surrounding structures. In some cases, digital subtraction angiography (DSA) may be employed for a more detailed view.
Treatment
Treatment of infectious intracranial aneurysms is complex and typically involves a combination of antimicrobial therapy and surgical or endovascular interventions. The choice of treatment depends on several factors, including the aneurysm's size, location, and the patient's overall health status. Antimicrobial therapy is tailored based on the identified organism and its antibiotic sensitivities. Surgical options may include aneurysm clipping or excision, while endovascular techniques can involve coil embolization or stenting.
Prognosis
The prognosis for patients with IIA varies and depends on the aneurysm's size, location, the causative organism, and the timeliness and effectiveness of treatment. Early diagnosis and appropriate treatment are crucial for improving outcomes. Without treatment, the risk of aneurysm rupture and subsequent SAH is high, which significantly increases morbidity and mortality rates.
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
